Mark Purcell
Stock Analyst at Morgan Stanley
(1.39)
# 3,530
Out of 5,012 analysts
6
Total ratings
66.67%
Success rate
-4.27%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Purcell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNY Sanofi | Upgrades: Overweight | $56 → $58 | $49.20 | +17.90% | 2 | Sep 8, 2025 | |
| NVS Novartis AG | Initiates: Equal-Weight | $114 | $131.55 | -13.34% | 1 | Jan 23, 2024 | |
| GSK GSK plc | Initiates: Equal-Weight | $44 | $43.50 | +1.15% | 1 | Jan 23, 2024 | |
| AZN AstraZeneca | Initiates: Overweight | $85 | $85.87 | -1.01% | 1 | Jan 23, 2024 | |
| NVO Novo Nordisk | Initiates: Overweight | $120 | $59.02 | +103.32% | 1 | Jan 23, 2024 |
Sanofi
Sep 8, 2025
Upgrades: Overweight
Price Target: $56 → $58
Current: $49.20
Upside: +17.90%
Novartis AG
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $114
Current: $131.55
Upside: -13.34%
GSK plc
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $44
Current: $43.50
Upside: +1.15%
AstraZeneca
Jan 23, 2024
Initiates: Overweight
Price Target: $85
Current: $85.87
Upside: -1.01%
Novo Nordisk
Jan 23, 2024
Initiates: Overweight
Price Target: $120
Current: $59.02
Upside: +103.32%